or Try an Advanced Search...

    Technical Analysis for OTLK - Outlook Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 8.29 -3.72% -0.32
    OTLK closed down 3.72 percent on Thursday, April 18, 2024, on 31 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical OTLK trend table...
    Date Alert Name Type % Chg
    Fell Below 50 DMA Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    20 DMA Resistance Bearish -3.72%
    Outside Day Range Expansion -3.72%
    Wide Bands Range Expansion -3.72%
    Oversold Stochastic Weakness -3.72%
    20 DMA Resistance Bearish -5.26%
    Narrow Range Bar Range Contraction -5.26%
    Wide Bands Range Expansion -5.26%
    Older End-of-Day Signals for OTLK ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout about 20 hours ago
    50 DMA Support about 21 hours ago
    Down 5% about 22 hours ago
    Down 3% about 22 hours ago
    Fell Below 50 DMA about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    OTLK Chart by TradingView
    Basic chart:

    Profile

    Outlook Therapeutics, Inc. Description

    Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with MTTR, LLC; IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was founded in 2010 and is headquartered in Cranbury, New Jersey.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Biopharmaceutical Life Sciences Antibodies Cancer Treatment Monoclonal Antibodies Monoclonal Antibody Ophthalmic Macular Degeneration Specialty Drugs Retina Wet Age Related Macular Degeneration Age Related Macular Degeneration

    Is OTLK a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 3 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 15 Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
    Apr 10 Insiders are Piling into These 10 Healthcare Stocks in 2024
    Apr 1 Insiders Buying Outlook Therapeutics And 2 Other Stocks
    Mar 31 Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval
    Mar 28 Outlook Therapeutics files for $300M mixed securities shelf
    Mar 27 Outlook Therapeutics shares rise after 'buy' rating from BTIG
    Mar 25 Outlook Therapeutics files to sell 21.43M common shares for holders
    Mar 22 Outlook Therapeutics stock jumps as EU backs new wet AMD treatment
    Mar 22 Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
    Mar 18 Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
    See more OTLK news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 40.6
    52 Week Low 4.004
    Average Volume 766,190
    200-Day Moving Average 12.56
    50-Day Moving Average 8.54
    20-Day Moving Average 9.08
    10-Day Moving Average 8.89
    Average True Range 1.06
    RSI (14) 47.92
    ADX 42.67
    +DI 30.45
    -DI 16.01
    Chandelier Exit (Long, 3 ATRs) 9.66
    Chandelier Exit (Short, 3 ATRs) 9.93
    Upper Bollinger Bands 10.90
    Lower Bollinger Band 7.26
    Percent B (%b) 0.28
    BandWidth 40.06
    MACD Line 0.07
    MACD Signal Line 0.21
    MACD Histogram -0.1409
    Fundamentals Value
    Market Cap 2.16 Billion
    Num Shares 260 Million
    EPS -0.24
    Price-to-Earnings (P/E) Ratio -34.54
    Price-to-Sales 13.27
    Price-to-Book 10.19
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.36
    Resistance 3 (R3) 9.42 9.13 9.18
    Resistance 2 (R2) 9.13 8.86 9.10 9.12
    Resistance 1 (R1) 8.71 8.69 8.56 8.65 9.06
    Pivot Point 8.42 8.42 8.34 8.38 8.42
    Support 1 (S1) 8.00 8.14 7.85 7.93 7.52
    Support 2 (S2) 7.70 7.97 7.67 7.46
    Support 3 (S3) 7.28 7.70 7.40
    Support 4 (S4) 7.22